Key result
Recommencement of warfarin and the use of Prothrombinex-VF resulted in the development of warfarin-induced skin necrosis in a single patient case.
Why the study?
The use of anticoagulation reversal agents such as Prothrombinex-VF in the development of warfarin-induced skin necrosis is not a commonly documented phenomenon.
Does the use of Prothrombinex-VF during warfarin recommencement contribute to the development of warfarin-induced skin necrosis?
Case Report (n=1)
Does the use of Prothrombinex-VF during warfarin recommencement contribute to the development of warfarin-induced skin necrosis?
Highlights a rare and potentially life-threatening case of warfarin-induced skin necrosis associated with the use of the anticoagulation reversal agent Prothrombinex-VF.
Alerts clinicians to possible WISN with Prothrombinex-VF on warfarin restart; hypothesis-generating case leaves open causality and need for validation.
Anticoagulant-induced skin necrosis is a rare and potentially life-threatening complication of anticoagulant therapy. The majority of cases of anticoagulant-induced skin necrosis have been attributed to warfarin, known as warfarin-induced skin necrosis (WISN). The use of anticoagulation reversal agents such as Prothrombinex-VF in the development of WISN is not a commonly documented phenomenon. The authors present a case of WISN post-recommencement of warfarin and the use of Prothrombinex-VF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a case report in Warfarin-induced skin necrosis (n=1). Warfarin and Prothrombinex-VF was evaluated on Development of warfarin-induced skin necrosis. Recommencement of warfarin and the use of Prothrombinex-VF resulted in the development of warfarin-induced skin necrosis in a single patient case.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: